Core Viewpoint - The company, Kelaiying (06821.HK), has announced that its board meeting will take place on October 30, 2025, to consider and approve the third-quarter performance for the nine months ending September 30, 2025, along with addressing other matters if necessary [1] Group 1 - The board meeting is scheduled for October 30, 2025 [1] - The meeting will focus on the approval of the company's third-quarter results for the nine months ending September 30, 2025 [1] - Other matters may also be addressed during the meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 凱萊英醫藥集團（天津）股份有限公司（「本公司」）董事會（「董事會」）謹此公佈， 董事會會議將於2025年10月30日（星期四）舉行，藉以（其中包括）考慮及批准本 公司及其附屬公司截至2025年9月30日止九個月的第三季度業績及其發佈，以及 處理其他事項（如有）。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，2025年10月15日 於本公告日期，本公司董事會由董事長兼執行董事Hao Hong博士，執行董事楊蕊 女士、張達先生及洪亮先生，非執行董事Ye Song博士及張婷女士，以及獨立非 執行董事孫雪嬌博士、侯欣一博士及謝維愷先生組成。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 董事會會議日期 ...

Group 1 - The 2025 European Society for Medical Oncology (ESMO) will be held in Berlin from October 17 to 21, with expectations for new data on domestic innovative drugs and potential business development (BD) opportunities [1] - Chinese innovative drug companies are rapidly gaining global competitiveness, with a significant increase in licensing-out transactions, totaling nearly $66 billion in the first half of 2025, surpassing the $51.9 billion for the entire year of 2024 [1] - The impact of tariff policies on China's pharmaceutical industry is limited, as the market has already priced in the expectations regarding drug tariffs [1] Group 2 - As of October 15, 2025, the Hong Kong innovative drug ETF (513120) has risen by 1.69%, with notable increases in constituent stocks such as WuXi AppTec and Kelun-Biotech [2] - The Hong Kong innovative drug ETF (513120) has reached a new high in shares at 16.552 billion, with a total scale exceeding 22 billion yuan, making it the largest in the Hong Kong pharmaceutical ETF market [2] - The innovative drug ETF (515120) has also seen a rise of 2.40%, with significant growth in constituent stocks, and has experienced a notable increase in scale over the past three months [2] Group 3 - The Hong Kong innovative drug ETF (513120) closely tracks the CSI Hong Kong Innovative Drug Index, which has a high concentration of biopharmaceuticals and chemical pharmaceuticals, accounting for 92.5% [2] - The innovative drug ETF (515120) tracks the CSI Innovative Drug Industry Index, covering various aspects of innovative drug development, production, and sales [3] - Both ETFs support T+0 trading, enhancing liquidity and capital efficiency for investors [3]

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于沪深300指数5%以上) [28] Core Insights - From January to August 2025, the overall medical insurance fund income maintained positive growth, with total income reaching 18809.94 billion yuan, a year-on-year increase of 6.91%. Total expenditure was 15432.20 billion yuan, a year-on-year decrease of 1.80%. The cumulative surplus for the same period was 3377.74 billion yuan, a year-on-year increase of 79.74% [2][3][13] - The surplus rate for January to August 2025 was 17.96%, an increase of 7.28 percentage points compared to the same period in 2024. The surplus rate for August 2025 was 11.62% [2][13][15] - The medical insurance fund's performance improved compared to 2024, with only May showing a deficit in monthly surplus [13] Summary by Sections Medical Insurance Fund Performance - The medical insurance fund income from January to August 2025 was 18809.94 billion yuan, with a year-on-year growth of 6.91%. Expenditure was 15432.20 billion yuan, down 1.80% year-on-year. The cumulative surplus was 3377.74 billion yuan, up 79.74% year-on-year [2][6][13] - The surplus rate for the same period was 17.96%, which is an improvement from the previous year [2][13] Employee and Resident Medical Insurance - Employee medical insurance income for January to August 2025 was 11954.62 billion yuan, a year-on-year increase of 5.43%. In August, the income was 1452.27 billion yuan, up 1.97% year-on-year. Expenditure for the same period was 8811.88 billion yuan, a year-on-year increase of 2.24% [3][21] - For residents, the income was 6855.32 billion yuan, a year-on-year increase of 9.59%, while expenditure decreased by 6.70% [21][26] Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with rich pipelines, such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group. It also highlights companies with significant single-product potential and those leading in advanced technology platforms [4][26] - In the CXO sector, companies like WuXi AppTec and Kelun Pharmaceutical are recommended, along with medical device companies that have been undervalued due to previous price pressures [4][26]

Group 1 - The stock price of Kailaiying has dropped 3.24% to 102.00 CNY per share, with a total market capitalization of 36.781 billion CNY, marking a cumulative decline of 10.29% over the last four days [1] - Kailaiying Pharmaceutical Group, established on October 7, 1998, specializes in providing CMO pharmaceutical outsourcing services, with revenue composition of 76.19% from small molecule CDMO solutions and 23.71% from emerging services [1] Group 2 - Huisheng Fund holds a significant position in Kailaiying, with its Huisheng Medical Health 6-Month Holding Period Mixed Fund reducing its holdings by 88,700 shares, now holding 345,300 shares, which constitutes 5.08% of the fund's net value [2] - The fund has experienced a floating loss of approximately 1.1809 million CNY today and a total floating loss of 4.0398 million CNY during the four-day decline [2] - The Huisheng Medical Health 6-Month Holding Period Mixed Fund was established on December 22, 2020, with a current size of 600 million CNY, achieving a year-to-date return of 23.82% and a one-year return of 19.48% [2]

Market Overview - The medical services sector experienced a decline of 2.91% on October 13, with Haoyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Stock Performance - Notable gainers in the medical services sector included: - Meinian Health: closed at 5.29, up 3.52% with a trading volume of 2.2848 million shares [1] - ST Biological: closed at 9.15, up 2.69% with a trading volume of 23,400 shares [1] - International Medical: closed at 4.98, up 2.26% with a trading volume of 356,400 shares [1] - Major decliners included: - Haoyuan Pharmaceutical: closed at 75.50, down 6.79% with a trading volume of 75,700 shares [2] - Boteng Co.: closed at 23.34, down 6.27% with a trading volume of 224,900 shares [2] - Kailaiying: closed at 105.42, down 5.04% with a trading volume of 57,800 shares [2] Capital Flow - The medical services sector saw a net outflow of 870 million yuan from institutional investors, while retail investors contributed a net inflow of 601 million yuan [2][3] - Key stocks with significant capital flow included: - Sanbo Brain Science: net inflow of 21.51 million yuan from institutional investors [3] - International Medical: net inflow of 20.51 million yuan from institutional investors [3] - Jiuzhou Pharmaceutical: net inflow of 10.59 million yuan from institutional investors [3]

Core Viewpoint - The Hong Kong pharmaceutical stocks continue to decline, particularly in the CRO sector, with significant drops in share prices for several companies [1] Group 1: Company Performance - Junshi Biosciences (01877.HK) decreased by 7.98%, trading at 27.22 HKD [1] - Kanglong Chemical (03759.HK) fell by 6.3%, with a price of 24.4 HKD [1] - Kelun Pharmaceutical (06821.HK) saw a decline of 5.69%, priced at 91.95 HKD [1] - Tigermed (03347.HK) dropped by 3.48%, trading at 42.4 HKD [1]

Group 1 - Pharmaceutical stocks continue to decline, with CRO sector leading the drop, including significant declines in Junshi Biosciences (down 7.98%), Kanglong Chemical (down 6.3%), Kelaiying (down 5.69%), and Tigermed (down 3.48%) [1] - Recent market trends in the pharmaceutical sector are attributed to several factors, including a deal between the Trump administration and Pfizer to lower drug prices in the U.S., which is seen as a reconciliation signal between U.S. pharmaceutical companies and the government [1] - The U.S. Senate's consideration of a bill to prohibit certain Chinese biotech companies from receiving federal funding has led to a significant pullback in the CXO sector [1] Group 2 - Recent tensions in U.S.-China trade relations have escalated, with a renewed tariff war expected; however, the pharmaceutical market is not overly concerned as the industry has shown resilience since the first tariff war in April [2] - The innovative drug and CXO sectors have outperformed other sub-industries, driven by China's rising independent innovation and ongoing overseas business development, which are less affected by tariffs [2] - The CXO sector benefits from strong upstream and downstream relationships and a service pricing model that allows companies to pass on tariff pressures relatively freely [2]

Group 1 - Pharmaceutical stocks continued to decline, with CRO sector leading the drop, including significant declines in companies like Junshi Biosciences (-7.98%), Kanglong Chemical (-6.3%), and others [1] - Recent market trends in the pharmaceutical sector are attributed to several factors, including a deal between the Trump administration and Pfizer to lower drug prices in the U.S., which is seen as a reconciliation signal between U.S. pharmaceutical companies and the government [1] - The U.S. Senate's consideration of a bill to prohibit certain Chinese biotech companies from receiving federal funding has led to a significant pullback in the CXO sector [1] Group 2 - Tensions in U.S.-China trade relations have escalated, with renewed tariff battles expected; however, the pharmaceutical market is not overly concerned as the industry has shown resilience [2] - The innovative drug and CXO sectors have performed exceptionally well since the first tariff battle in April, driven by China's rising independent innovation and ongoing overseas business development [2] - The CXO sector's strong business model allows companies to transfer tariff pressures relatively freely due to strong upstream and downstream relationships [2]

Investment Rating - The report indicates a positive investment outlook for the China cell therapy CDMO industry, highlighting its transition from technological exploration to large-scale commercialization [4]. Core Insights - The China cell therapy CDMO industry is at a critical stage of transitioning from technology exploration to large-scale commercialization, supported by favorable policies and increasing clinical pipeline activity [4]. - The industry is experiencing significant growth in demand due to the acceleration of clinical trials and product approvals, which is driving the need for CDMO services [21][26]. - The report emphasizes the importance of technological innovation and operational efficiency in enhancing the competitiveness of CDMO companies in the global market [12][29]. Summary by Sections Industry Overview - The CDMO industry is driven by high R&D costs and risks, with biotech companies emerging as key players supported by capital and policy initiatives [9]. - The industry is entering a golden development period, with a shift from scale expansion to a focus on technological depth and global expansion [10]. Demand Analysis - Global research output in cell therapy is continuously increasing, leading to higher demands for production processes and quality control [21]. - The approval of cell therapy products in China is accelerating, which enhances the demand for CDMO services to address complex production challenges [26]. Supply Analysis - CDMO companies are experiencing revenue growth with stable gross margins, indicating a strong technical drive and sustainable development capabilities [28]. - The industry is witnessing a significant differentiation, with leading companies maintaining market positions while smaller firms face structural challenges [29]. Capacity Expansion - The CDMO industry is entering a phase of large-scale capacity expansion, with multiple companies establishing new GMP production facilities to meet future commercial production demands [32][33]. Market Size Analysis - The cell therapy CDMO market is showing a clear growth trajectory, with projections indicating a significant increase in market size from 2025 to 2030 due to more pipelines entering late-stage clinical trials and commercialization [35][37].